CMAUP Plant Collective Molecular Activities

Plant Name: Urtica dioica

Taxonomic Information:

Plant ID: NPO23017
Plant Latin Name: Urtica dioica
Taxonomy Genus: Urtica
Taxonomy Family: Urticaceae

Plant External Links:

NCBI TaxonomyDB: 3501
Plant-of-the-World-Online: 260630-2

Used in Medicines:

Country/Region:

Turkey; Albania; Italy; Turkmenistan; India; Finland; Lithuania; Sweden; China; Lebanon; Argentina; Spain; Bulgaria

Traditional Medicine System:

TCM; Homeopathy; Ayurveda

Medicinal Functions:

Antiasthmatic; Antidandruff; Antirheumatic; Antiseborrheic; Astringent; Diuretic; Galactogogue; Haemostatic; Hypoglycaemic; Stings; Tonic

Geographical Distribution:

Brazil; Turkey; Italy; Turkmenistan; Lebanon; Lithuania; France; Ireland; Argentina; Bolivia; Norway; Belarus; Algeria; Iceland; China; Chile; Belgium; Germany; Spain; Ukraine; Eritrea; Netherlands; Libya; Denmark; Poland; Finland; United States; Morocco; Sweden; Switzerland; New Zealand; Russia; Bulgaria; Romania; Albania; Portugal; South Africa; Tunisia; India; United Kingdom; Austria; Colombia; Greece; Hungary

Example Image

Geographical Distribution

See the Plant Occurrence Worldwide with Latitude and Longitude Available

Collective Molecular Activities of the Plant

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 1μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins
Small molecule receptor (family A GPCR)	HRH3; HRH4; ADORA3; HRH1; HTR7; HTR5A; HTR1F; HTR1B; DRD2; HTR4; HTR1D; HTR1E; HTR2B; HTR2A; HTR1A; HTR2C; HTR6; DRD3;
Peptide receptor (family A GPCR)	TSHR; NPSR1;
5HT3 receptor	HTR3A;
Protein Kinase	MET; AXL; FLT3; CDK1; PIM1; IGF1R; KDR; AURKB;
Lyase	CA12; CA9; CA7;
Oxidoreductase	TYR;
Enzyme_unclassified	HSD17B2; HSD17B10; ALOX12; NOX4; POLB;
Metallo protease	MMP9; MMP1; MMP2;
Transcription Factor	AHR; NFKB1;
SLC superfamily of solute carriers	SLCO1B1;
Unclassified	LMNA;

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 1μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:	CYP1A2; CYP1B1; CYP1A1;

Detailed Information of Target Proteins

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID
5HT3 receptor	HTR3A	Serotonin 3a (5-HT3a) receptor	P46098	CHEMBL1899
Cytochrome P450 family 1	CYP1A2	Cytochrome P450 1A2	P05177	CHEMBL3356
Cytochrome P450 family 1	CYP1B1	Cytochrome P450 1B1	Q16678	CHEMBL4878
Cytochrome P450 family 1	CYP1A1	Cytochrome P450 1A1	P04798	CHEMBL2231
Enzyme_unclassified	HSD17B2	Estradiol 17-beta-dehydrogenase 2	P37059	CHEMBL2789
Enzyme_unclassified	HSD17B10	Endoplasmic reticulum-associated amyloid beta-peptide-binding protein	Q99714	CHEMBL4159
Enzyme_unclassified	ALOX12	Arachidonate 12-lipoxygenase	P18054	CHEMBL3687
Enzyme_unclassified	NOX4	NADPH oxidase 4	Q9NPH5	CHEMBL1250375
Enzyme_unclassified	POLB	DNA polymerase beta	P06746	CHEMBL2392
Lyase	CA12	Carbonic anhydrase XII	O43570	CHEMBL3242
Lyase	CA9	Carbonic anhydrase IX	Q16790	CHEMBL3594
Lyase	CA7	Carbonic anhydrase VII	P43166	CHEMBL2326
Metallo protease	MMP9	Matrix metalloproteinase 9	P14780	CHEMBL321
Metallo protease	MMP1	Matrix metalloproteinase-1	P03956	CHEMBL332
Metallo protease	MMP2	Matrix metalloproteinase-2	P08253	CHEMBL333
Oxidoreductase	TYR	Tyrosinase	P14679	CHEMBL1973
Peptide receptor (family A GPCR)	TSHR	Thyroid stimulating hormone receptor	P16473	CHEMBL1963
Peptide receptor (family A GPCR)	NPSR1	Neuropeptide S receptor	Q6W5P4	CHEMBL5162
Protein Kinase	AURKB	Serine/threonine-protein kinase Aurora-B	Q96GD4	CHEMBL2185
Protein Kinase	MET	Hepatocyte growth factor receptor	P08581	CHEMBL3717
Protein Kinase	AXL	Tyrosine-protein kinase receptor UFO	P30530	CHEMBL4895
Protein Kinase	FLT3	Tyrosine-protein kinase receptor FLT3	P36888	CHEMBL1974
Protein Kinase	CDK1	Cyclin-dependent kinase 1	P06493	CHEMBL308
Protein Kinase	PIM1	Serine/threonine-protein kinase PIM1	P11309	CHEMBL2147
Protein Kinase	IGF1R	Insulin-like growth factor I receptor	P08069	CHEMBL1957
Protein Kinase	KDR	Vascular endothelial growth factor receptor 2	P35968	CHEMBL279
SLC superfamily of solute carriers	SLCO1B1	Solute carrier organic anion transporter family member 1B1	Q9Y6L6	CHEMBL1697668
Small molecule receptor (family A GPCR)	HRH3	Histamine H3 receptor	Q9Y5N1	CHEMBL264
Small molecule receptor (family A GPCR)	HRH4	Histamine H4 receptor	Q9H3N8	CHEMBL3759
Small molecule receptor (family A GPCR)	ADORA3	Adenosine A3 receptor	P0DMS8	CHEMBL256
Small molecule receptor (family A GPCR)	HRH1	Histamine H1 receptor	P35367	CHEMBL231
Small molecule receptor (family A GPCR)	HTR7	Serotonin 7 (5-HT7) receptor	P34969	CHEMBL3155
Small molecule receptor (family A GPCR)	HTR5A	Serotonin 5a (5-HT5a) receptor	P47898	CHEMBL3426
Small molecule receptor (family A GPCR)	HTR1F	Serotonin 1f (5-HT1f) receptor	P30939	CHEMBL1805
Small molecule receptor (family A GPCR)	HTR1B	Serotonin 1b (5-HT1b) receptor	P28222	CHEMBL1898
Small molecule receptor (family A GPCR)	DRD2	Dopamine D2 receptor	P14416	CHEMBL217
Small molecule receptor (family A GPCR)	HTR4	Serotonin 4 (5-HT4) receptor	Q13639	CHEMBL1875
Small molecule receptor (family A GPCR)	HTR1D	Serotonin 1d (5-HT1d) receptor	P28221	CHEMBL1983
Small molecule receptor (family A GPCR)	HTR1E	Serotonin 1e (5-HT1e) receptor	P28566	CHEMBL2182
Small molecule receptor (family A GPCR)	HTR2B	Serotonin 2b (5-HT2b) receptor	P41595	CHEMBL1833
Small molecule receptor (family A GPCR)	HTR2A	Serotonin 2a (5-HT2a) receptor	P28223	CHEMBL224
Small molecule receptor (family A GPCR)	HTR1A	Serotonin 1a (5-HT1a) receptor	P08908	CHEMBL214
Small molecule receptor (family A GPCR)	HTR2C	Serotonin 2c (5-HT2c) receptor	P28335	CHEMBL225
Small molecule receptor (family A GPCR)	HTR6	Serotonin 6 (5-HT6) receptor	P50406	CHEMBL3371
Small molecule receptor (family A GPCR)	DRD3	Dopamine D3 receptor	P35462	CHEMBL234
Transcription Factor	AHR	Aryl hydrocarbon receptor	P35869	CHEMBL3201
Transcription Factor	NFKB1	Nuclear factor NF-kappa-B p105 subunit	P19838	CHEMBL3251
Unclassified	LMNA	Prelamin-A/C	P02545	CHEMBL1293235

Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
BP	GO:0009987; cellular process	GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway	3.356E-11	2.030E-08	HTR1A, HTR1B, HTR5A, HTR7
BP	Unclassified;	GO:0042310; vasoconstriction	7.747E-11	4.559E-08	HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7
MF	GO:0060089; molecular transducer activity	GO:0004969; histamine receptor activity	5.015E-10	2.540E-07	HRH1, HRH3, HRH4, HTR6
BP	GO:0008283; cell proliferation	GO:0008284; positive regulation of cell proliferation	1.998E-09	9.257E-07	ALOX12, CDK1, DRD2, DRD3, FLT3, HTR1A, HTR1B, HTR2A, HTR2B, IGF1R, KDR, MMP2, MMP9, PIM1, TSHR
BP	GO:0009987; cellular process	GO:0002031; G-protein coupled receptor internalization	1.093E-08	4.409E-06	DRD2, DRD3, HTR1B, HTR2B
BP	GO:0032501; multicellular organismal process	GO:0097746; regulation of blood vessel diameter	2.242E-08	8.003E-06	HRH1, HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR7
BP	Unclassified;	GO:2000021; regulation of ion homeostasis	4.120E-08	1.339E-05	CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C, KDR, NPSR1
BP	GO:0008152; metabolic process	GO:0010513; positive regulation of phosphatidylinositol biosynthetic process	1.435E-07	3.634E-05	HTR2A, HTR2B, HTR2C
BP	GO:0009987; cellular process	GO:0014059; regulation of dopamine secretion	6.576E-07	1.432E-04	DRD2, DRD3, HTR1B, HTR2A
BP	GO:0065007; biological regulation	GO:0007194; negative regulation of adenylate cyclase activity	1.147E-06	2.333E-04	DRD2, DRD3, HRH3, HRH4
BP	GO:0008152; metabolic process	GO:0097267; omega-hydroxylase P450 pathway	1.707E-06	3.124E-04	CYP1A1, CYP1A2, CYP1B1
BP	GO:0050896; response to stimulus	GO:0034776; response to histamine	2.343E-06	4.082E-04	DRD2, DRD3, HRH1
BP	GO:0065007; biological regulation	GO:0010817; regulation of hormone levels	3.835E-06	6.175E-04	CYP1A1, CYP1B1, DRD2, HSD17B2, HTR1A, HTR2A, HTR2C, NFKB1, SLCO1B1
BP	GO:0051179; localization	GO:0051209; release of sequestered calcium ion into cytosol	4.640E-06	7.268E-04	DRD2, HTR2A, HTR2B, HTR2C
MF	GO:0005488; binding	GO:0019825; oxygen binding	4.640E-06	7.268E-04	CYP1A1, CYP1A2, CYP1B1, NOX4
BP	GO:0023052; signaling	GO:0051967; negative regulation of synaptic transmission, glutamatergic	5.142E-06	7.941E-04	DRD2, HTR1B, HTR2A
BP	GO:0009987; cellular process	GO:0007208; phospholipase C-activating serotonin receptor signaling pathway	6.047E-06	9.081E-04	HTR2A, HTR2C
MF	GO:0005488; binding	GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	6.047E-06	9.081E-04	HTR2A, HTR2C
BP	GO:0009987; cellular process	GO:0043066; negative regulation of apoptotic process	6.157E-06	9.120E-04	ALOX12, AURKB, AXL, CDK1, HTR2B, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1
MF	GO:0003824; catalytic activity	GO:0004089; carbonate dehydratase activity	6.417E-06	9.441E-04	CA12, CA7, CA9
MF	GO:0005488; binding	GO:0051378; serotonin binding	6.476E-30	3.737E-26	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7
BP	GO:0009987; cellular process	GO:0007210; serotonin receptor signaling pathway	3.288E-26	7.955E-23	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7
MF	GO:0060089; molecular transducer activity	GO:0004993; G-protein coupled serotonin receptor activity	3.288E-26	7.955E-23	HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7
BP	GO:0009987; cellular process	GO:0070374; positive regulation of ERK1 and ERK2 cascade	8.959E-06	1.267E-03	DRD2, HTR2A, HTR2B, HTR2C, KDR, NOX4
BP	GO:0050896; response to stimulus	GO:0033993; response to lipid	9.028E-06	1.268E-03	AXL, CA9, CYP1A1, CYP1A2, FLT3, HSD17B2, HTR1B, HTR5A, NFKB1, TYR
BP	GO:0050896; response to stimulus	GO:0045471; response to ethanol	9.979E-06	1.384E-03	CDK1, DRD3, HTR1B, HTR3A, POLB
BP	GO:0007610; behavior	GO:0048148; behavioral response to cocaine	1.594E-05	2.103E-03	DRD2, DRD3, HTR2A
BP	GO:0050896; response to stimulus	GO:0010035; response to inorganic substance	1.642E-05	2.154E-03	AXL, CDK1, CYP1A1, CYP1A2, CYP1B1, DRD2, KDR, MMP9
BP	GO:0009987; cellular process	GO:0060160; negative regulation of dopamine receptor signaling pathway	1.811E-05	2.348E-03	DRD2, DRD3
BP	GO:0008152; metabolic process	GO:0019373; epoxygenase P450 pathway	1.856E-05	2.392E-03	CYP1A1, CYP1A2, CYP1B1
BP	GO:0008283; cell proliferation	GO:1904707; positive regulation of vascular smooth muscle cell proliferation	2.145E-05	2.716E-03	HTR1B, MMP2, MMP9
BP	GO:0032502; developmental process	GO:0007568; aging	2.211E-05	2.783E-03	AURKB, CDK1, CYP1A1, HTR2A, NOX4, POLB
BP	GO:0008152; metabolic process	GO:0009404; toxin metabolic process	2.463E-05	3.047E-03	CYP1A1, CYP1A2, CYP1B1
MF	GO:0003824; catalytic activity	GO:0070330; aromatase activity	2.463E-05	3.047E-03	CYP1A1, CYP1A2, CYP1B1
BP	GO:0008152; metabolic process	GO:0018894; dibenzo-p-dioxin metabolic process	3.617E-05	3.998E-03	CYP1A1, CYP1A2
BP	GO:0032501; multicellular organismal process	GO:0014827; intestine smooth muscle contraction	3.617E-05	3.998E-03	HTR1D, HTR2B
BP	GO:0008152; metabolic process	GO:0018958; phenol-containing compound metabolic process	4.183E-05	4.554E-03	DRD2, DRD3, HTR1A, TYR
BP	GO:0050896; response to stimulus	GO:0071417; cellular response to organonitrogen compound	5.068E-05	5.409E-03	HRH1, HTR1B, IGF1R, MMP2, NFKB1, NOX4, TSHR
BP	GO:0040011; locomotion	GO:0090325; regulation of locomotion involved in locomotory behavior	6.018E-05	6.240E-03	DRD2, DRD3
BP	GO:0050896; response to stimulus	GO:0071502; cellular response to temperature stimulus	6.018E-05	6.240E-03	HTR1B, HTR2B
BP	GO:0023052; signaling	GO:0032228; regulation of synaptic transmission, GABAergic	6.790E-05	6.804E-03	CA7, DRD2, HTR1B
BP	GO:0032502; developmental process	GO:0021885; forebrain cell migration	8.913E-05	8.259E-03	AXL, DRD2, HTR6
BP	GO:0050896; response to stimulus	GO:0006954; inflammatory response	9.283E-05	8.458E-03	ADORA3, AXL, HRH1, HRH4, NFKB1, NOX4, POLB
BP	GO:0008152; metabolic process	GO:0018108; peptidyl-tyrosine phosphorylation	9.602E-05	8.639E-03	AXL, FLT3, IGF1R, KDR, MET
BP	GO:0008152; metabolic process	GO:0006730; one-carbon metabolic process	9.707E-05	8.662E-03	CA12, CA7, CA9
BP	GO:0050896; response to stimulus	GO:0014075; response to amine	1.143E-04	9.766E-03	CDK1, DRD2, DRD3
MF	Unclassified;	GO:0004872; receptor activity	9.785E-18	1.522E-14	ADORA3, AHR, AXL, DRD2, DRD3, FLT3, HRH1, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, TSHR
CC	GO:0044425; membrane part	GO:0005887; integral component of plasma membrane	1.845E-16	2.231E-13	ADORA3, AXL, DRD2, DRD3, FLT3, HRH1, HRH3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, SLCO1B1, TSHR

Enriched KEGG Pathways of Target Proteins (Activity≤1μM)

Top 10 KEGG Pathways (ordered by adjusted p-value)

Detailed Information of Enriched KEGG Pathways

Pathway Category Top Level	Pathway Category Second Level	Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
09130 Environmental Information Processing	09133 Signaling molecules and interaction	hsa04080	Neuroactive ligand-receptor interaction	2.108E-23	2.466E-21	HTR1E, HTR1F, HTR1D, HTR1A, HTR2B, HTR1B, HTR2C, HTR2A, HTR5A, HTR4, TSHR, HTR6, HRH1, HTR7, HRH3, ADORA3, HRH4, DRD2, DRD3
09150 Organismal Systems	09156 Nervous system	hsa04726	Serotonergic synapse	5.299E-21	3.100E-19	HTR1E, HTR1F, HTR1D, HTR1A, HTR2B, HTR1B, HTR2C, ALOX12, HTR3A, HTR2A, HTR5A, HTR4, HTR6, HTR7
09130 Environmental Information Processing	09132 Signal transduction	hsa04024	cAMP signaling pathway	3.570E-11	1.392E-09	HTR6, HTR1E, HTR1F, HTR1D, HTR1A, HTR1B, HTR4, DRD2, NFKB1, TSHR
09130 Environmental Information Processing	09132 Signal transduction	hsa04020	Calcium signaling pathway	1.022E-08	2.990E-07	HTR6, HRH1, HTR7, HTR2B, HTR2C, HTR2A, HTR5A, HTR4
09150 Organismal Systems	09157 Sensory system	hsa04742	Taste transduction	4.539E-08	1.062E-06	HTR1E, HTR1F, HTR1D, HTR1A, HTR1B, HTR3A
09150 Organismal Systems	09157 Sensory system	hsa04750	Inflammatory mediator regulation of TRP channels	3.693E-06	6.172E-05	HRH1, HTR2B, HTR2C, ALOX12, HTR2A
09140 Cellular Processes	09144 Cellular community - eukaryotes	hsa04540	Gap junction	2.169E-06	4.229E-05	CDK1, HTR2B, HTR2C, HTR2A, DRD2
09150 Organismal Systems	09152 Endocrine system	hsa04913	Ovarian steroidogenesis	6.201E-06	9.069E-05	HSD17B2, CYP1A1, CYP1B1, IGF1R
09160 Human Diseases	09161 Cancers	hsa05200	Pathways in cancer	4.204E-05	4.472E-04	FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R
09100 Metabolism	09103 Lipid metabolism	hsa00140	Steroid hormone biosynthesis	1.126E-05	1.318E-04	CYP1A2, HSD17B2, CYP1A1, CYP1B1
09160 Human Diseases	09161 Cancers	hsa05205	Proteoglycans in cancer	1.232E-04	1.012E-03	MMP2, KDR, MMP9, MET, IGF1R
09160 Human Diseases	09161 Cancers	hsa05202	Transcriptional misregulation in cancer	6.990E-05	6.815E-04	FLT3, MMP9, MET, NFKB1, IGF1R
09130 Environmental Information Processing	09132 Signal transduction	hsa04014	Ras signaling pathway	2.074E-04	1.517E-03	HTR7, KDR, MET, NFKB1, IGF1R
09100 Metabolism	09105 Amino acid metabolism	hsa00380	Tryptophan metabolism	1.204E-04	1.012E-03	CYP1A2, CYP1A1, CYP1B1
09160 Human Diseases	09161 Cancers	hsa05221	Acute myeloid leukemia	3.466E-04	2.385E-03	FLT3, PIM1, NFKB1
09160 Human Diseases	09161 Cancers	hsa05206	MicroRNAs in cancer	7.090E-04	4.416E-03	PIM1, CYP1B1, MMP9, MET, NFKB1
09160 Human Diseases	09161 Cancers	hsa05219	Bladder cancer	1.297E-04	1.012E-03	MMP1, MMP2, MMP9
09130 Environmental Information Processing	09132 Signal transduction	hsa04015	Rap1 signaling pathway	1.629E-03	9.077E-03	KDR, DRD2, MET, IGF1R
09160 Human Diseases	09166 Endocrine and metabolic diseases	hsa04933	AGE-RAGE signaling pathway in diabetic complications	1.833E-03	9.750E-03	MMP2, PIM1, NFKB1
09100 Metabolism	09111 Xenobiotics biodegradation and metabolism	hsa00980	Metabolism of xenobiotics by cytochrome P450	7.172E-04	4.416E-03	CYP1A2, CYP1A1, CYP1B1
09160 Human Diseases	09161 Cancers	hsa05204	Chemical carcinogenesis	1.006E-03	5.884E-03	CYP1A2, CYP1A1, CYP1B1
09100 Metabolism	09102 Energy metabolism	hsa00910	Nitrogen metabolism	8.616E-06	1.120E-04	CA12, CA7, CA9

Human Diseases Associated with the Target Proteins of the Plant

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Associated Disease Targets (Association Ref: TTD database)
H60-H95: Diseases of the ear and mastoid process	Vertigo meniere's disease	H81, H81.0, R42	HRH1;
NA: NA	Sleep initiation and maintenance disorders	NA	HTR2C;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep maintenance insomnia	F51.0, G47.0	HTR2A;
L00-L99: Diseases of the skin and subcutaneous tissue	Pruritus	L29	HRH1;
J00-J99: Diseases of the respiratory system	Airway inflammation	J00-J99	FLT3;
C00-D49: Neoplasms	Advanced solid tumor	C00-C75, C7A, C7B	MET;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Advanced stage Parkinson's disease	F02.3, G20	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Alcohol use disorders	F10.2	DRD2; HTR2A; HTR2C; HRH3;
L00-L99: Diseases of the skin and subcutaneous tissue	Vitiligo	L80	TYR;
NA: NA	Vomiting	NA	DRD2; HRH1; HTR3A;
NA: NA	Vertigo's disease	NA	HRH1;
C00-D49: Neoplasms	Liver cancer	C22	IGF1R; KDR;
G00-G99: Diseases of the nervous system G00-G99	Lateral sclerosis	G12.2	HTR1A;
NA: NA	Meniere's disease	NA	HRH1;
L00-L99: Diseases of the skin and subcutaneous tissue	Melasma	L81.1	TYR;
NA: NA	Bulimia nervosa	NA	HTR1A;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychotic disorders	F20-F29	DRD2; DRD3; HTR2C; HTR1A; HTR1B;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychoses	F20-F29	HTR2B;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychiatric disorder	F01-F99	HTR2A; HTR1A;
L00-L99: Diseases of the skin and subcutaneous tissue	Allergic skin disorders	L00-L99	HRH1;
S00-T88: Injury, poisoning and certain other consequences of external causes	Allergy	T78.4	DRD2; HRH1;
NA: NA	Allergic disorders	NA	HRH1;
C00-D49: Neoplasms	Allergic conjunctivitis	C91.0, H10, H10.45, T78.4	HRH1;
C00-D49: Neoplasms	AML	NA	KDR; FLT3;
NA: NA	Vasomotor rhinitis	NA	HRH1;
C00-D49: Neoplasms	Lymphoma	C81-C86	CA9;
C00-D49: Neoplasms	Lung cancer	C33-C34	MMP2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Local anaesthetic	R20.0	HTR3A;
K00-K95: Diseases of the digestive system	Liver disease	K70-K77	MET;
I00-I99: Diseases of the circulatory system	Cerebral infarction	I63	HTR2B;
G00-G99: Diseases of the nervous system G00-G99	Central nervous system disease	G00-G99	HTR2A; HRH3;
NA: NA	Cervical dystonia	NA	HTR1A;
H00-H59: Diseases of the eye and adnexa	Ophthalmic disease	H00-H59	DRD2;
C00-D49: Neoplasms	Aggressive non-hodgkin's lymphoma	C81, C81-C86, C82-C85, C91-C95	HTR2C;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sexual dysfunction	F52	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Severe mood disorders	F30-F39	HTR1A; HTR1D;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep disorders	F51, G47	HTR7; HRH1; HTR2A; HRH3;
C00-D49: Neoplasms	Prostate cancer	C61	FLT3;
L00-L99: Diseases of the skin and subcutaneous tissue	Psoriasis	L40	FLT3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Male sexual disorders	F52	DRD3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Major depressive disorder	F32, F33, M32	HTR7; DRD2; HTR2C; HTR1A; HTR1B; HTR1D;
I00-I99: Diseases of the circulatory system	Maintain blood pressure in hypotensive states	I10	DRD2;
A00-B99: Certain infectious and parasitic diseases	Malaria	B54	ADORA3;
I00-I99: Diseases of the circulatory system	Cardiac failure	I50	DRD2;
I00-I99: Diseases of the circulatory system	Cardiovascular disorder	I00-I99	KDR; HTR2A;
I00-I99: Diseases of the circulatory system	Cardiotonic	I50	DRD2;
C00-D49: Neoplasms	Squamous cell cancer of head and neck	NA	KDR;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Spasm	R25.2	HTR1A;
C00-D49: Neoplasms	Solid tumours	C00-D48	MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; CA9;
NA: NA	Social phobia	NA	HTR1A;
C00-D49: Neoplasms	Advanced renal cell carcinoma	C64	KDR;
C00-D49: Neoplasms	Advanced malignancies	C00-C96	KDR;
C00-D49: Neoplasms	Melanoma	C43	KDR; TYR;
C00-D49: Neoplasms	Medullary thyroid cancer	C73	KDR;
NA: NA	Malignant phaeochromocytoma	NA	DRD2;
NA: NA	Malignant essential hypertension	NA	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Carcinoid syndrome	E34.0	DRD2;
C00-D49: Neoplasms	Cancer	C00-C96	PIM1; MET; CDK1; IGF1R; KDR; NFKB1; FLT3; ADORA3; HRH1; MMP9; MMP2; CA9;
J00-J99: Diseases of the respiratory system	Bronchitis	J20-J21, J42	DRD2;
NA: NA	Peripheral sensory neuropathies	NA	HTR1A;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Rheumatoid arthritis	M05-M06	MMP1; TYR; HRH4;
NA: NA	Addiction	NA	HTR2A;
E00-E89: Endocrine, nutritional and metabolic diseases	Metabolic disorders	E70-E89	HTR2C; HRH3;
C00-D49: Neoplasms	Metastasis	C00-C97	AXL;
C00-D49: Neoplasms	Metastatic castration-resistant prostate cancer	C61	KDR;
NA: NA	Schizoaffective disorder	NA	HTR1A;
J00-J99: Diseases of the respiratory system	Seasonal and perennial allergic rhinitis and vasomotor rhinitis	J30	HRH1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	HTR7; DRD2; DRD3; HTR2A; HTR2C; HTR6; HTR1A; HRH3;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Fibromyalgia	M79.7	HTR2A; HTR3A;
L00-L99: Diseases of the skin and subcutaneous tissue	Fibrosis	L90.5	MET; DRD2;
C00-D49: Neoplasms	Acute myeloid leukemia	C92.0	AURKB; FLT3;
C00-D49: Neoplasms	Acute lymphoblastic leukemia	C91.0	FLT3;
C00-D49: Neoplasms	Metastatic HER2-negative gastric cancer	NA	MET;
C00-D49: Neoplasms	Metastatic colorectal cancer	C18-C21	KDR;
G00-G99: Diseases of the nervous system G00-G99	Migraine headaches	G43	DRD2; HTR2C; HTR1B; HTR1D;
G00-G99: Diseases of the nervous system G00-G99	Migraine	G43	HTR2A; HTR2B; HTR1F; HTR1A; HTR1D;
G00-G99: Diseases of the nervous system G00-G99	Mild to moderate alzheimer disease	G30	HRH3;
NA: NA	Benign prostatic hypertrophy	NA	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Bipolar disorder	F31, F40-F42	DRD2;
C00-D49: Neoplasms	Biliary cancer	C22, C24	KDR;
N00-N99: Diseases of the genitourinary system	Urinary incontinence	N39.3, N39.4, R32	HTR1A;
NA: NA	Primary insomnia	NA	HTR2C;
C00-D49: Neoplasms	Cutaneous Melanoma	C43-C44	KDR;
C00-D49: Neoplasms	Glioma	C71	KDR;
C00-D49: Neoplasms	Gliosarcoma	NA	FLT3;
C00-D49: Neoplasms	Glioblastoma	NA	FLT3;
NA: NA	GIST	NA	FLT3;
H00-H59: Diseases of the eye and adnexa	Glaucoma	H40-H42	ADORA3; DRD2; HTR2A;
K00-K95: Diseases of the digestive system	Ulcerative colitis	K51	MMP9;
C00-D49: Neoplasms	Metastatic breast cancer	C50	KDR;
C00-D49: Neoplasms	Breast cancer	C50	CDK1; IGF1R; KDR; FLT3; DRD2; CA9;
C00-D49: Neoplasms	Hepatocellular carcinoma	C22.0	MET; IGF1R; KDR; ADORA3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Generalized anxiety disorder	F32, F40-F42, F41.1	HTR2C; HTR1A;
K00-K95: Diseases of the digestive system	Gastroesophageal reflux disease	K21	HTR3A;
C00-D49: Neoplasms	Gastrointestinal cancers	C15-C26	KDR;
K00-K95: Diseases of the digestive system	Gastrointestinal problems	K30-K31, Q40-Q41	DRD2;
I00-I99: Diseases of the circulatory system	Stroke	I61-I63, I80-I82	MMP9;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Substance dependence	F10-F19	DRD2;
C00-D49: Neoplasms	Head and neck cancer	C07-C14, C32-C33	KDR;
I00-I99: Diseases of the circulatory system	Heart disease	I00-I52	MET;
K00-K95: Diseases of the digestive system	Chemotherapy-induced mucositis	K12.3	MET;
I00-I99: Diseases of the circulatory system	Pulmonary arterial hypertension	I27.0, I27.2	HTR2B;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychosis	F20-F29	DRD2;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Osteoarthritis	M15-M19, M47	MMP2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Anesthesia	R20.0	HRH1;
C00-D49: Neoplasms	Thyroid cancer	C73	KDR; TSHR;
H00-H59: Diseases of the eye and adnexa	Graves' ophthalmopathy	H06.2	IGF1R;
J00-J99: Diseases of the respiratory system	Hay fever	J30	HRH1;
NA: NA	Itching	NA	DRD2; HRH1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Depression	F30-F39	HRH1; HTR2A; HTR2B; HTR2C; HTR1A;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetes	E23.2, N25.1	HTR2A; HTR2C;
NA: NA	HIV infections	NA	AHR;
E00-E89: Endocrine, nutritional and metabolic diseases	Hormone deficiency	E00-E90	IGF1R;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Premature ejaculation	F52.4	HTR1A;
NA: NA	False perceptions	NA	DRD2;
I00-I99: Diseases of the circulatory system	Cerebrovascular ischaemia	I61-I63	ADORA3; DRD2;
C00-D49: Neoplasms	Inflammatory disease	C11, C44, K75.9, M00-M25	DRD2; HRH4;
NA: NA	Episode	NA	HTR1A;
NA: NA	Hematopoietic stem cell transplantation	NA	FLT3;
NA: NA	Hepatitis C virus infection	NA	ADORA3;
I00-I99: Diseases of the circulatory system	Hemorrhoids	I84	HTR2A;
C00-D49: Neoplasms	Hematological malignancies	C81-C86	AURKB;
C00-D49: Neoplasms	Peritoneal cavity cancer	NA	KDR;
NA: NA	Peripheral vasoconstriction	NA	DRD2;
H00-H59: Diseases of the eye and adnexa	Ocular allergy	H00-H59	HRH1;
K00-K95: Diseases of the digestive system	Gastric motility disorder	K22.4	DRD3;
C00-D49: Neoplasms	Gastric cancer	C16	KDR;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Female sexual dysfunction	F52	DRD3; HTR1A;
G00-G99: Diseases of the nervous system G00-G99	Acute migraine	G43	HTR1D;
I00-I99: Diseases of the circulatory system	Coronary heart disease	I25.1	HTR2B;
I00-I99: Diseases of the circulatory system	Pulmonary hypertension	I27.0, I27.2	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Mood disorder	F30-F39	HTR2A; HTR2C; HTR1A; HTR1B; HTR1D;
NA: NA	Morning sickness	NA	HRH1;
E00-E89: Endocrine, nutritional and metabolic diseases	Hyperprolactinemia	E22.1	DRD2;
NA: NA	Hypersensitivity reactions	NA	HRH1;
I00-I99: Diseases of the circulatory system	Hypertension	I10-I16	DRD2; HTR1A;
J00-J99: Diseases of the respiratory system	Asthma	J45	DRD2; HRH1; HRH4;
M00-M99: Diseases of the musculoskeletal system and connective tissue	Arthritis	M00-M25	MMP1;
E00-E89: Endocrine, nutritional and metabolic diseases	Erythropoietic porphyria	E80.0	HTR2A;
G00-G99: Diseases of the nervous system G00-G99	Epilepsy	G40	HTR1D; HRH3;
NA: NA	Corneal vascularity	NA	DRD2;
I00-I99: Diseases of the circulatory system	Coronary artery disease	I20-I25	HTR1A;
G00-G99: Diseases of the nervous system G00-G99	Neurodegenerative disease	G30-G32	HTR6;
G00-G99: Diseases of the nervous system G00-G99	Motor neurone disease	G12.2	IGF1R;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Huntington's disease	F02.2, G10	DRD2;
A00-B99: Certain infectious and parasitic diseases	Human immunodeficiency virus infection	B20-B26	FLT3;
NA: NA	Hyperaemia	NA	DRD2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Growth failure	R62.8	IGF1R;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Attention deficit hyperactivity disorder	F90	HRH3;
A00-B99: Certain infectious and parasitic diseases	Bacterial infections	A00-B99	DRD2;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Excessive daytime sleepiness	F51.1, G47.1	HRH3;
C00-D49: Neoplasms	Colon cancer	C50	FLT3;
I00-I99: Diseases of the circulatory system	Congestive heart failure	I50	HTR2B;
NA: NA	Common cold	NA	HRH1;
L00-L99: Diseases of the skin and subcutaneous tissue	Psoriatic disorder	L40	IGF1R;
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	Idiopathic thrombocytopenic purpura	D69.3	DRD2;
NA: NA	Coughs	NA	HRH1;
E00-E89: Endocrine, nutritional and metabolic diseases	Eating disorder	E66, F50, I10-I16, I50	HTR1A; HRH3;
C00-D49: Neoplasms	Pancreatic cancer	C25	KDR; FLT3; MMP2;
C00-D49: Neoplasms	Malignant adrenal gland cancer	C74.0	IGF1R;
C00-D49: Neoplasms	Leukemia	C90-C95	FLT3;
NA: NA	Perennial and seasonal allergic rhinitis	NA	HRH1;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Musculoskeletal pain	R52, G89	HRH3;
C00-D49: Neoplasms	Multiple myeloma	C90	IGF1R; AHR;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Hypoactive sexual desire disorder	F52.0	HTR1A;
I00-I99: Diseases of the circulatory system	Hypotension	I95	DRD2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Emesis	R11	DRD2; DRD3; HTR6; HTR3A;
NA: NA	Schizoaffective disorders	NA	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Obese insulin-resistant disorders	E11	HRH3;
C00-D49: Neoplasms	Non-small cell lung cancer	C33-C34	MET; IGF1R; KDR; AXL; DRD2;
C00-D49: Neoplasms	Non-small-cell lung cancer	NA	KDR; MMP2;
E00-E89: Endocrine, nutritional and metabolic diseases	Obesity	E66	HRH1; HTR2C; HTR6; HRH3;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic neuropathy	E11.40	HRH3;
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetic nephropathy	E11.21	MMP1;
C00-D49: Neoplasms	Fallopian tube cancer	C57.0, D28.2	KDR;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Dry cough	R05	HRH1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Drug abuse	F10-F19	DRD3; HTR2C;
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure	Diagnostic test to differentiate primary and secondary hypothyroidism	W88	TSHR;
C00-D49: Neoplasms	Colorectal cancer	C18-C21	IGF1R; KDR; FLT3; MMP9;
G00-G99: Diseases of the nervous system G00-G99	Alzheimer disease	G30	DRD2; HTR6; HTR1A; HRH3;
J00-J99: Diseases of the respiratory system	Allergic rhinitis	J00, J30, J31.0, T78.4	HRH1; HRH3; HRH4;
J00-J99: Diseases of the respiratory system	Nasal congestion	J34.89	DRD2; HRH1;
G00-G99: Diseases of the nervous system G00-G99	Narcolepsy	G47.4	HRH3;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Cough	R05	HRH1;
I00-I99: Diseases of the circulatory system	Neurological disease	I21, I22, R52, R52.1-R52.2, R60.9, G89	NPSR1; HTR2C; HTR6; HRH3;
L00-L99: Diseases of the skin and subcutaneous tissue	Acne vulgaris	L70.0	MMP2;
E00-E89: Endocrine, nutritional and metabolic diseases	Acromegaly	E22.0	DRD2;
C00-D49: Neoplasms	Myeloid leukemia	C92	FLT3;
C00-D49: Neoplasms	Myelofibrosis	C94.4, D47.4	FLT3;
C00-D49: Neoplasms	Myelodysplastic syndrome	D46	KDR;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Dementia	F01-F07	HTR6; HRH3;
K00-K95: Diseases of the digestive system	Dermal necrosis	K05	DRD2;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Depressive fatigue	R53.82	DRD2;
J00-J99: Diseases of the respiratory system	Rhinitis	J00, J30, J31.0	HRH1;
O00-O9A: Pregnancy, childbirth and the puerperium	Postpartum haemorrhage	O72	DRD2;
NA: NA	Anaplastic mixed oligoastrocytoma	NA	FLT3;
I00-I99: Diseases of the circulatory system	Ischemia	I99.8	ADORA3;
NA: NA	Inflammatory diseases	NA	DRD2;
K00-K95: Diseases of the digestive system	Inflammatory bowel disease	K50, K51	DRD2;
E00-E89: Endocrine, nutritional and metabolic diseases	Inflammation	E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89	ADORA3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Insomnia	F51.0, G47.0	DRD2; HRH1;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cognitive disorders	F01-F07, F04, F05, R41.3	HTR6; HTR1A; HRH3;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cocaine addiction	F14.2	DRD3;
C00-D49: Neoplasms	CLL	NA	FLT3;
C00-D49: Neoplasms	Clear cell renal cell carcinoma	C64	CA9;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Chronic schizophrenics	F20	HTR1B;
J00-J99: Diseases of the respiratory system	Chronic obstructive pulmonary disease	J40-J44, J47	DRD2;
K00-K95: Diseases of the digestive system	Pancreatitis	K85, K86.0K86.1	HTR2A;
G00-G99: Diseases of the nervous system G00-G99	Parkinson's disease	G20	DRD2; HRH1; HTR1A;
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	CDK1; IGF1R; DRD2; HRH1; HTR2C; HTR1A; HRH3;
NA: NA	Urticaria	NA	HRH1;
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Nausea	R11	DRD2; HRH1; HTR3A;
J00-J99: Diseases of the respiratory system	Respiratory disease	J00-J99	HRH1;
C00-D49: Neoplasms	Renal cell carcinoma	NA	KDR; MMP2;
C00-D49: Neoplasms	Renal cancer	C64	KDR; CA9;
NA: NA	Respiratory allergies	NA	HRH1;
NA: NA	Anxiety disorders	NA	HTR1A;
I00-I99: Diseases of the circulatory system	Angina pectoris	I20	DRD2;
I00-I99: Diseases of the circulatory system	Angiogenesis disorder	I00-I99	KDR;
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Anxiety disorder	F32, F40-F42	DRD2; HRH1; HTR2A; HTR2C; HTR6; HTR1A; HTR1B; HRH3;
E00-E89: Endocrine, nutritional and metabolic diseases	Type 2 diabetes	E11	NFKB1;
C00-D49: Neoplasms	Thyroid cancer diagnosis	C73	TSHR;
A00-B99: Certain infectious and parasitic diseases	Irritable bowel syndrome	A09, K58, K59.1	HTR2B; HTR3A;
C00-D49: Neoplasms	Ovarian cancer	C56	KDR; MMP2;

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases